St Kilda, VIC, Australia Clinical Trials

A listing of St Kilda, VIC, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 73 clinical trials
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.

Research Site
 (3.5 away) Contact site
  • 07 Jul, 2021
  • +10 other locations
Study to Assess Safety Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

The primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the …

Peter MacCallum Cancer Centre
 (3.5 away) Contact site
  • 25 Jun, 2021
  • +27 other locations
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.

Alfred Health ( Site 0018)
 (2.3 away) Contact site
  • 26 Jun, 2021
  • +52 other locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

Investigational Site Number 0360001
 (3.0 away) Contact site
  • 14 Jun, 2021
  • +8 other locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

Research Site
 (8.8 away) Contact site
  • 20 Jul, 2021
  • +28 other locations
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the …

Peter MacCallum Cancer Centre
 (3.5 away) Contact site
  • 24 Jul, 2021
  • +68 other locations
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

The purpose of the first phase of the study is to determine whether, and at what dose, depsipeptide, bortezomib and dexamethasone can be safely administered to patients with Multiple Myeloma. The second phase of the study will establish whether depsipeptide, bortezomib and dexamethasone is effective in the treatment of patients …

maintenance therapy
monoclonal protein
growth factor
Peter MacCallum Cancer Centre
 (3.6 away) Contact site
  • 07 Nov, 2020
  • 1 location
A Study to Evaluate the Safety and Tolerability of EXN407

This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved Diabetic Macular Oedema (DMO), with Centre-subfield macular thickness (CMT) between 280-420 m and Best corrected visual acuity (BCVA) …

Centre for Eye Research Australia (CERA)
 (3.3 away) Contact site
  • 23 Jun, 2021
  • +9 other locations
Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single doses of ARO-ENaC in healthy adult volunteers; and to evaluate the safety, tolerability, PK and efficacy of multiple doses of ARO-ENaC in patients with pulmonary cystic fibrosis.

pulmonary function test
Research Site
 (4.6 away) Contact site
  • 28 Jul, 2021
  • +6 other locations
Umbrella Study of Sasanlimab Combined With Targeted Therapies in Participants With Non Small Cell Lung Cancer

Phase 1b/Phase 2 open-label, multi-center, parallel group umbrella study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. The Phase1b part of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 part. The Phase …

cancer chemotherapy
measurable disease
lung carcinoma
Austin Health
 (9.1 away) Contact site
  • 01 Aug, 2021
  • +42 other locations